BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1358409)

  • 1. Antitumor activity of tiazofurin in human colon carcinoma HT-29.
    Zhen W; Jayaram HN; Weber G
    Cancer Invest; 1992; 10(6):505-11. PubMed ID: 1358409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tiazofurin: molecular and clinical action.
    Weber G; Prajda N; Abonyi M; Look KY; Tricot G
    Anticancer Res; 1996; 16(6A):3313-22. PubMed ID: 9042306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on the mechanism of action of 2-beta-D-ribofuranosylthiazole-4-carboxamide--V. Factors governing the response of murine tumors to tiazofurin.
    Ahluwalia GS; Jayaram HN; Plowman JP; Cooney DA; Johns DG
    Biochem Pharmacol; 1984 Apr; 33(8):1195-203. PubMed ID: 6143562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on the mechanism of action of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide). VI. Biochemical and pharmacological studies on the degradation of thiazole-4-carboxamide adenine dinucleotide (TAD).
    Ahluwalia GS; Cooney DA; Marquez VE; Jayaram HN; Johns DG
    Biochem Pharmacol; 1986 Nov; 35(21):3783-90. PubMed ID: 2877671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of thiazole-4-carboxamide adenine dinucleotide (TAD) levels in mononuclear cells of leukemic patients treated with tiazofurin.
    Zhen W; Jayaram HN; Weber G
    Biochem Pharmacol; 1991 Jan; 41(2):281-6. PubMed ID: 1989637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical consequences of resistance to tiazofurin in human myelogenous leukemic K562 cells.
    Jayaram HN; Zhen W; Gharehbaghi K
    Cancer Res; 1993 May; 53(10 Suppl):2344-8. PubMed ID: 8097964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzyme-pattern-targeted chemotherapy with tiazofurin and allopurinol in human leukemia.
    Weber G; Jayaram HN; Lapis E; Natsumeda Y; Yamada Y; Yamaji Y; Tricot GJ; Hoffman R
    Adv Enzyme Regul; 1988; 27():405-33. PubMed ID: 2907968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of IMP dehydrogenase activity and guanylate metabolism by tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide).
    Lui MS; Faderan MA; Liepnieks JJ; Natsumeda Y; Olah E; Jayaram HN; Weber G
    J Biol Chem; 1984 Apr; 259(8):5078-82. PubMed ID: 6143752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition by tiazofurin of inosine 5'-phosphate dehydrogenase (IMP DH) activity in extracts of ovarian carcinomas.
    Look KY; Sutton GP; Natsumeda Y; Eble JN; Stehman FB; Ehrlich CE; Olah E; Prajda N; Bosze P; Eckhardt S
    Gynecol Oncol; 1992 Oct; 47(1):66-70. PubMed ID: 1358769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targets and markers of selective action of tiazofurin.
    Weber G; Natsumeda Y; Pillwein K
    Adv Enzyme Regul; 1985; 24():45-65. PubMed ID: 2424286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical mechanisms of resistance to tiazofurin.
    Jayaram HN
    Adv Enzyme Regul; 1985; 24():67-89. PubMed ID: 3835825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tiazofurin down-regulates expression of c-Ki-ras oncogene in a leukemic patient.
    Weber G; Nagai M; Natsumeda Y; Eble JN; Jayaram HN; Paulik E; Zhen WN; Hoffman R; Tricot G
    Cancer Commun; 1991 Mar; 3(3):61-6. PubMed ID: 1705812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of resistance to tiazofurin in hepatoma 3924A.
    Jayaram HN; Pillwein K; Lui MS; Faderan MA; Weber G
    Biochem Pharmacol; 1986 Feb; 35(4):587-93. PubMed ID: 2868729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on the antitumor activity and biochemical actions of cyclopentenyl cytosine against human colon carcinoma HT-29 in vitro and in vivo.
    Gharehbaghi K; Zhen W; Fritzer-Szekeres M; Szekeres T; Jayaram HN
    Life Sci; 1999; 64(2):103-12. PubMed ID: 10069488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationships between the cytotoxicity of tiazofurin and its metabolism by cultured human lung cancer cells.
    Carney DN; Ahluwalia GS; Jayaram HN; Cooney DA; Johns DG
    J Clin Invest; 1985 Jan; 75(1):175-82. PubMed ID: 2856924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective sensitivity to tiazofurin of human leukemic cells.
    Jayaram HN; Pillwein K; Nichols CR; Hoffman R; Weber G
    Biochem Pharmacol; 1986 Jun; 35(12):2029-32. PubMed ID: 3718544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of biochemical parameters of benzamide riboside, a new inhibitor of IMP dehydrogenase, with tiazofurin and selenazofurin.
    Gharehbaghi K; Sreenath A; Hao Z; Paull KD; Szekeres T; Cooney DA; Krohn K; Jayaram HN
    Biochem Pharmacol; 1994 Oct; 48(7):1413-9. PubMed ID: 7945441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential impact of tiazofurin and ribavirin on the enzymic program of the bone marrow.
    Prajda N; Hata Y; Abonyi M; Singhal RL; Weber G
    Cancer Res; 1993 Dec; 53(24):5982-6. PubMed ID: 7903199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IMP dehydrogenase: inhibition by the anti-leukemic drug, tiazofurin.
    Yamada Y; Natsumeda Y; Yamaji Y; Jayaram HN; Tricot GJ; Hoffman R; Weber G
    Leuk Res; 1989; 13(2):179-84. PubMed ID: 2564451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
    Tricot GJ; Jayaram HN; Lapis E; Natsumeda Y; Nichols CR; Kneebone P; Heerema N; Weber G; Hoffman R
    Cancer Res; 1989 Jul; 49(13):3696-701. PubMed ID: 2567208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.